ONCT — Oncternal Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $1.56m
- -$13.02m
- $0.79m
Annual cashflow statement for Oncternal Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -34.2 | -17.2 | -31.3 | -44.2 | -39.5 |
| Non-Cash Items | 20 | 1.41 | 6.04 | 7.54 | 6.04 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -2.51 | -1.68 | -1.3 | -0.069 | 1.27 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -16.7 | -17.5 | -26.6 | -36.7 | -32.2 |
| Other Investing Cash Flow Items | 16.1 | 0 | — | -26.5 | 0.651 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 16.1 | 0 | — | -26.5 | 0.651 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.015 | 114 | 0.617 | 9.58 | 1.07 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.594 | 96.7 | -26 | -53.6 | -30.4 |